Abstract
We conducted a cross-sectional online survey of adults (n = 1639; 56.3% women) self-reporting past or current psychedelic use. We investigated whether psychedelic use was associated with self-reported changes in the use of other substances. Participants reported substantial changes, with 43.8% (n = 651/1488) decreasing or ceasing alcohol use, 42.5% (n = 272/640) ceasing or decreasing antidepressant use, and 42.4% (n = 200/471) decreasing or ceasing cocaine use. The highest rates of increased use were for cannabis (10.9%; n = 151/1383) and tobacco products (9.3%; n = 60/646). The most common reasons for substance use reductions were feeling more connected with self (73%; n = 632), nature (55%; n = 476), and others (54.6%; n = 473), as well as feeling less anxious or depressed (59.4%; n = 514). Factors associated with reduction in any substance use included motivation to treat a medical condition, number of psychedelics used, younger age, and using both microdoses and macrodoses. This real-world evidence should be rigorously investigated in future studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Argento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. (2019). Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an indigenous community in Canada. Drug and Alcohol Review, 38(7), 781–789
Best, D., Sondhi, A., Brown, L., Nisic, M., Nagelhout, G. E., Martinelli, T., Van de Mheen, D., & Vanderplasschen, W. (2021). The Strengths and Barriers Recovery Scale (SABRS): relationships matter in building strengths and overcoming barriers. Frontiers in Psychology, 12, 663447
Boehnke, K. F., Davis, A. K., & McAfee, J. (2022). Applying lessons from Cannabis to the psychedelic highway: Buckle up and build infrastructure. JAMA Health Forum, 3(6), e221618. https://doi.org/10.1001/jamahealthforum.2022.1618
Boehnke, K. F., Gagnier, J. J., Matallana, L., & Williams, D. A. (2021). Substituting cannabidiol for opioids and pain medications among individuals with fibromyalgia: A large online survey. The Journal of Pain, 22(11), 1418–1428. https://doi.org/10.1016/j.jpain.2021.04.011
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Williams, D. A., & Clauw, D. J. (2019). Pills to pot: Observational analyses of cannabis substitution among medical cannabis users with chronic pain. The Journal of Pain, 20(7), 830–841. https://doi.org/10.1016/j.jpain.2019.01.010
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2022.2096
Cacioppo, J. T., & Cacioppo, S. (2018). The growing problem of loneliness. The Lancet, 391(10119), 426
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
Champagne, J.-R., & Ramadan, S. R. (2022). Health Canada finally restores access to psychedelics. Retrieved from https://www.fasken.com/en/knowledge/2022/01/health-canada-finally-restores-access-to-psychedelics. Accessed 2 Apr 2023.
Clements, A. D., Unterrainer, H.-F., & Cook, C. C. (2022). Human connection as a treatment for addiction. Frontiers in Psychology, 13
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285
DiVito, A. J., & Leger, R. F. (2020). Psychedelics as an emerging novel intervention in the treatment of substance use disorder: A review. Molecular Biology Reports, 47(12), 9791–9799. https://doi.org/10.1007/s11033-020-06009-x
Earp, B. D., Lewis, J., Hart, C. L., & Reform, B. A. P. F. D. P. (2021). Racial justice requires ending the war on drugs. The American Journal of Bioethics, 21(4), 4–19. https://doi.org/10.1080/15265161.2020.1861364
Fuentes, J. J., Fonseca, F., Elices, M., Farre, M., & Torrens, M. (2019). Therapeutic use of LSD in psychiatry: A systematic review of randomized-controlled clinical trials. Frontiers in Psychiatry, 10, 943. https://doi.org/10.3389/fpsyt.2019.00943
Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2019a). Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry, 10, 955. https://doi.org/10.3389/fpsyt.2019.00955
Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019b). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/10.1177/0269881119845793
Glynos, N. G., Fields, C. W., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2022). Naturalistic psychedelic use: A world apart from clinical care. Journal of Psychoactive Drugs, 1-10. https://doi.org/10.1080/02791072.2022.2108356
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., & Malievskaia, E. (2022). Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 387(18), 1637–1648. https://doi.org/10.1056/NEJMoa2206443
Holman, A., Kruger, D. J., Lucas, P., Ong, K., Bergmans, R. S., & Boehnke, K. F. (2022). Healthcare provider and medical cannabis patient communication regarding referral and medication substitution: The Canadian context. Journal of Cannabis Research, 4(1), 32. https://doi.org/10.1186/s42238-022-00141-0
Joca, S. R., Sartim, A. G., Roncalho, A. L., Diniz, C. F., & Wegener, G. (2019). Nitric oxide signalling and antidepressant action revisited. Cell and Tissue Research, 377, 45–58
Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992. https://doi.org/10.1177/0269881114548296
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics, 197, 83–102. https://doi.org/10.1016/j.pharmthera.2018.11.010
Lindsay, B. (2022). Footage of therapists spooning and pinning down patient in B.C. trial for MDMA therapy prompts review. Retrieved from https://www.cbc.ca/news/canada/british-columbia/bc-mdma-therapy-videos-1.6400256. Accessed 2 Apr 2023.
Lucas, P., Boyd, S., Milloy, M. J., & Walsh, Z. (2021). Cannabis significantly reduces the use of prescription opioids and improves quality of life in authorized patients: Results of a large prospective study. Pain Medicine, 22(3), 727–739. https://doi.org/10.1093/pm/pnaa396
Lucas, P., Walsh, Z., Crosby, K., Callaway, R., Belle-Isle, L., Kay, R., Capler, R., & Holtzman, S. (2016). Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 35(3), 326–333. https://doi.org/10.1111/dar.12323
MacBride, K. (2021). Psychedelic-assisted therapy is bigger than ever, but it’s at risk of being compromised by alleged abuse. Retrieved from https://www.inverse.com/mind-body/grossbard-bourzat-psychedelic-assisted-therapy-abuse. Accessed 1 Dec 2022.
Moens, J. (2023). For Canadian patients, therapeutic psychedelics beset by red tape. Retrieved from https://undark.org/2023/03/08/for-canadian-patients-palliative-psychedelics-beset-by-red-tape/. Accessed 2 Apr 2023
Nagele, P., Zorumski, C. F., & Conway, C. (2018). Exploring nitrous oxide as treatment for mood disorders: Basic concepts. Journal of Clinical Psychopharmacology, 38(2), 144
Nichols, D. E., Nichols, C. D., & Hendricks, P. S. (2023). Proposed consensus statement on defining psychedelic drugs. Psychedelic Medicine, 1(1), 12–13. https://doi.org/10.1089/psymed.2022.0008
Perkins, D., Sarris, J., Rossell, S., Bonomo, Y., Forbes, D., Davey, C., Hoyer, D., Loo, C., Murray, G., Hood, S., Schubert, V., & Castle, D. (2021). Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Australian & New Zealand Journal of Psychiatry, 0004867421998785. https://doi.org/10.1177/0004867421998785
Pettersen, H., Landheim, A., Skeie, I., Biong, S., Brodahl, M., Oute, J., & Davidson, L. (2019). How social relationships influence substance use disorder recovery: A collaborative narrative study. Substance Abuse: Research and Treatment, 13, 1178221819833379
Pietrabissa, G., & Simpson, S. G. (2020). Psychological consequences of social isolation during COVID-19 outbreak. Frontiers in Psychology, 11, 2201
St. Arnaud, K. O., & Sharpe, D. (2023). Contextual parameters associated with positive and negative mental health in recreational psychedelic users. Journal of Psychoactive Drugs, 55(1), 30–39. https://doi.org/10.1080/02791072.2022.2039815
Thomas, G., Lucas, P., Capler, N. R., Tupper, K. W., & Martin, G. (2013). Ayahuasca-assisted therapy for addiction:Results from a preliminary observational study in Canada. Current Drug Abuse Reviews, 6(1), 30–42. https://doi.org/10.2174/15733998113099990003
Varias, A., van Roessel, P., Parsiani, M., Filippou-Frye, M., Neylan, T. C., Nagele, P., Yesavage, J., Clark, J. D., & Rodriguez, C. I. (2020). Does nitrous oxide help veterans with posttraumatic stress disorder? A case series. The Journal of Clinical Psychiatry, 81(4). https://doi.org/10.4088/JCP.20l13393
Watts, R., Kettner, H., Geerts, D., Gandy, S., Kartner, L., Mertens, L., Timmermann, C., Nour, M. M., Kaelen, M., Carhart-Harris, R., & Nutt, D. (2022). The Watts Connectedness Scale: A new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology, 239(11), 3461–3483
Wesselmann, E. D., & Parris, L. (2021). Exploring the links between social exclusion and substance use, misuse, and addiction. Frontiers in Psychology, 12, 2321
Yaden, D. B., Haidt, J., Hood, R. W., Jr., Vago, D. R., & Newberg, A. B. (2017). The varieties of self-transcendent experience. Review of General Psychology, 21(2), 143–160
Acknowledgements
The authors would like to thank all the participants in this study for taking the time to fill up our survey, and MAPS PBC, SABI Mind, and Psygen for co-sponsoring the Canadian Psychedelic Survey.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
The study was co-sponsored by SABI Mind, the Multidisciplinary Association of Psychedelic Studies Public Benefits Corp. (MAPS PBC), and Psygen.
Ethics and Consent
The survey was ethics reviewed by Advarra (protocol # Pro00059863).
Consent to Participate
Online informed consent was obtained from all the study participants.
Competing Interests
Dr. Boehnke has received grant funding from Tryp Therapeutics and Algae Sciences. He sits on a Data Safety and Monitoring Committee (unpaid) for Vireo Health. Dr. Boehnke’s effort on this publication was partially supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K01DA049219 (KFB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Philippe Lucas PhD is President of SABI Mind, one of the co-sponsors of this study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Boehnke, K.F., Kruger, D.J. & Lucas, P. Changed Substance Use After Psychedelic Experiences Among Individuals in Canada. Int J Ment Health Addiction (2023). https://doi.org/10.1007/s11469-023-01085-z
Accepted:
Published:
DOI: https://doi.org/10.1007/s11469-023-01085-z